Stromal cell-derived factor-1 recruits putative endothelial progenitor cells for neoangiogenesis and support endometriosis lesion development

2012 ◽  
Vol 94 (1) ◽  
pp. 116
Author(s):  
S. Virani ◽  
A.K. Edwards ◽  
E. Kerr ◽  
R. Thomas ◽  
T. Childs ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Stromal Cell ◽  
Endothelial Progenitor ◽  
Lesion Development ◽  
Stromal Cell Derived Factor

scholarly journals Exercise Induces Stromal Cell–Derived Factor-1α–Mediated Release of Endothelial Progenitor Cells with Increased Vasculogenic Function

2015 ◽  
Vol 135 (2) ◽  
pp. 340e-350e ◽  
Author(s):  
Edwin Chang ◽  
Josemaria Paterno ◽  
Dominik Duscher ◽  
Zeshaan N. Maan ◽  
Jerry S. Chen ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Stromal Cell ◽  
Endothelial Progenitor ◽  
Stromal Cell Derived Factor

scholarly journals Platelet-Derived Stromal Cell–Derived Factor-1 Regulates Adhesion and Promotes Differentiation of Human CD34+Cells to Endothelial Progenitor Cells

Circulation ◽  
2008 ◽  
Vol 117 (2) ◽  
pp. 206-215 ◽  
Author(s):  
Konstantinos Stellos ◽  
Harald Langer ◽  
Karin Daub ◽  
Tanja Schoenberger ◽  
Alexandra Gauss ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Stromal Cell ◽  
Endothelial Progenitor ◽  
Human Cd34 ◽  
Cd34 Cells ◽  
Stromal Cell Derived Factor

scholarly journals Active Stromal Cell–Derived Factor 1α and Endothelial Progenitor Cells are Equally Increased by Alogliptin in Good and Poor Diabetes Control

2017 ◽  
Vol 10 ◽  
pp. 117955141774398 ◽  
Author(s):  
Roberto Negro ◽  
Eupremio Luigi Greco ◽  
Giacomo Greco
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Stromal Cell ◽  
Diabetes Control ◽  
Diabetic Patients ◽  
Endothelial Progenitor ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Group A ◽  
Stromal Cell Derived Factor ◽  
Group B

Background: It is postulated that the ability of dipeptidyl peptidase-4 inhibitors (DPP-4-i) to increase circulating endothelial progenitor cells (EPCs) may be at least partly mediated by active stromal cell–derived factor 1α (SDF-1α) (a pivotal mediator of stem cell mobilization from the bone marrow). As other DPP-4-i were demonstrated to increase EPC concentrations, in this study, we sought to investigate the ability of the DPP-4-i alogliptin in modifying EPCs and SDF-1α, in patients with good and poor diabetes control. Methods: Two groups of diabetic patients on metformin were divided by hemoglobin A1c (HbA1c): Group A—those with HbA1c ≤6.5% (28 patients) and Group B—those with HbA1c 7.5% to 8.5% (31 patients). Both groups received alogliptin 25 mg/daily for 4 months. At baseline and 4 months later, clinical, laboratory parameters, EPCs, and active SDF-1α were determined. Results: After 4-month treatment with alogliptin, either Group A or Group B showed reduced HbA1c levels and concomitant similar increase in EPCs and active SDF-1α. Conclusions: Alogliptin showed significant benefits in increasing EPCs and active SDF-1α either in good or poor diabetes control. The study demonstrated that similar to other DPP-4-i, also alogliptin is able to increase EPC concentrations, suggesting the existence of a class effect mediated by SDF-1α. The extent of increase in EPCs is independent from baseline diabetes control.

Sign in / Sign up

Export Citation Format

Share Document